 |
|
June 13, 2025 |
| Covering
Life Sciences Drugs, Diagnostics,
Devices, Digital Health |
|
|
|
* may need subscription to view |
 |
- ANI Pharmaceuticals: Presentation of New
Preclinical Data More
- Celldex: Unprecedented 76 Week Results From
Barzolvolimab Phase 2 Study in Chronic
Spontaneous Urticaria at EAACI Congress 2025
More
- Hoth Therapeutics: Secures Japanese Patent
for Breakthrough HT-KIT Platform Targeting
Mast Cell Diseases
More
- Merck: FDA Approves KEYTRUDA (pembrolizumab)
for PD-L1+ Resectable Locally Advanced Head
& Neck Squamous Cell Carcinoma as
Neoadjuvant Treatment, Continued as Adjuvant
Treatment Combined With Radiotherapy With or
Without Cisplatin Then as a Single Agent More
More*
- Mitsubishi Tanabe Pharma America: Advances
Oncology Pipeline: First Patient Dosed in
MT-4561 Trial for Advanced Solid Tumors More
- Schrödinger: Encouraging Initial Phase 1
Clinical Data for SGR-1505 at EHA Annual
Congress More
More*
- Starton Therapeutics: Phase 2a Clinical
Trial for Continuous Low-Dose Lenalidomide
(STAR-LLD) in Multiple Myeloma Open for
Enrollment More
- Syndax: New Revuforj (revumenib) Data in
Relapsed/Refractory mNPM1 and NUP98r Acute
Leukemia From AUGMENT-101 Trial at EHA 2025
More
- Syndax: Publication of Revumenib Data From
the BEAT AML Trial in the Journal of Clinical
Oncology and Simultaneous Presentation at EHA
2025 More
- Tonix Pharmaceuticals: Appointment of
Commercial Industry Veteran, James “Jim”
Hunter, to Board of Directors More
- Tris Pharma: To Debut Positive Results of
Intranasal (Snorting) Human Abuse Potential
Study of Cebranopadol, an Investigational
First-In-Class Oral Dual-NMR Agonist for the
Treatment of Moderate-to-Severe Pain, at the
2025 CPDD Annual Meeting More
- UroGen: U.S. FDA Approves ZUSDURI
(mitomycin) for Intravesical Solution as the
First and Only Medication for Recurrent
Low-Grade Intermediate-Risk Non-Muscle
Invasive Bladder Cancer (LG-IR-NMIBC) More
More*
More* More*
|
|
 |
- LSN: Hot Investor Mandates (Updated 6/10) More
- More on Insmed Aiming to Raise $750M
in One of the Largest Stock Offerings This
Year More*
More*
More*
More*
|
|
|
- Bristol Myers CEO Stays Bullish on Cobenfy
Despite Trial Flop, Signs of Slowing Momentum
More
- Bristol Myers Gets a Key Strategist With
‘Team Shibs’ More*
- Regeneron Genetics Center Launches
Proteomics Study of 200K Geisinger Samples
Using Olink Platform More*
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: NYC Life Science Company
Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
Feature your company |
|
Apply to have your company
showcased by Big4Bio. |
|
|
|
|
|
 |
|
Premier Executive Search and
Talent Advisory Firm Slone
Partners Launches Fractional
Talent Service to Deliver
On-Demand Leaders and Specialists
|
|
Learn More
→ |
|
|
- Feature: The Future of Hiring: How
Fractional Talent is Reshaping the Workplace
More
- HBCUs Can Help Create a 21st-Century
Bioeconomy and the Talent Pipeline It Requires
More*
- ICYMI: Beyond Cautious Optimism: Why a
Hybrid Talent Model is the Future for Life
Sciences & Healthcare More
- 9 Companies Hiring in New Jersey More
- Sire Search Reveals Top 5 Websites to
Accelerate Pharma Careers
More
- The Top 12 Companies Hiring in Biopharma Now
More
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:NYC,
all rights reserved 2025
© 2025
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
